Swedish Orphan Biovitrum AB

Type: Company
Name: Swedish Orphan Biovitrum AB (Biovitrum AB)
Nationality: Sweden
Web Address: http://www.biovitrum.com/
Fact Sheet: Fact Sheet for Biovitrum AB
First reported Apr 16 2014 - Updated Apr 16 2014 - 3 reports

Swedish Orphan Biovitrum Publishes Annual Report 2013

Swedish Orphan Biovitrum AB (publ) (Sobi) today published its Annual Report for 2013, themed "Pioneer in Rare Diseases", on the company's website, www.sobi.com. Help employers find you! Check out all the jobs and post your resume. ... [Published BioSpace - Apr 16 2014]
First reported Apr 14 2014 - Updated Apr 15 2014 - 2 reports

Auxilium, Sobi present data from clinical trials evaluating the use of Xiaflex/Xiapex in adult patients with PD at EAU Congress

Auxilium Pharmaceuticals, Inc., a fully integrated specialty biopharmaceutical company, and Swedish Orphan Biovitrum AB (Sobi), an international specialty healthcare company dedicated to rare diseases, have presented encore data from multiple clinical ... [Published PharmaBiz - Apr 15 2014]
First reported Apr 14 2014 - Updated Apr 14 2014 - 1 reports

Biogen and Sobi announce positive results from Phase III hemophilia A study

Biogen Idec, a biotechnology company, and Swedish Orphan Biovitrum AB, or Sobi, have announced positive top-line results from the Kids A-LONG Phase III clinical study that evaluated the safety and efficacy of ELOCTATE, an investigational recombinant factor ... [Published Individual.com - Apr 14 2014]
First reported Apr 10 2014 - Updated Apr 11 2014 - 12 reports

Hemophilia drug draws plaudits

Biotech drugmaker Biogen Idec (BIIB) and its partner Swedish Orphan Biovitrum announced positive results for Eloctate, their experimental hemophilia A drug. In a late-stage study, the blood-clotting drug "was generally well-tolerated, and no inhibitors ... [Published Yahoo! Finance - Apr 11 2014]
First reported Apr 10 2014 - Updated Apr 10 2014 - 3 reports

UPDATE 1-Biogen's blood disorder drug succeeds in late-stage trial

(Adds details, background, stock movement)April 10 (Reuters) - Biogen Idec Inc and Swedish Orphan Biovitrum said their experimental blood disorder drug was effective in treating children with hemophilia in a late-stage trial.The drug, Eloctate, was able ... [Published CNBC - Apr 10 2014]
First reported Apr 07 2014 - Updated Apr 07 2014 - 5 reports

Swedish Orphan Biovitrum Becomes Market Authorisation Holder For Xiapex In Europe

-- Swedish Orphan Biovitrum AB (publ) (Sobi) and Auxilium Pharmaceuticals, Inc. (Nasdaq: AUXL) today announced that Sobi became the Market Authorisation Holder (MAH) for Xiapex® (collagenase clostridium histolyticum), in 28 EU member countries, Norway, ... [Published BioSpace - Apr 07 2014]
First reported Apr 03 2014 - Updated Apr 04 2014 - 6 reports

Sobi gets exclusive commercial rights to TiGenix's ChondroCelect

Related Biotechnology, Pharmaceutical and Healthcare NewsUnder a ten-year agreement, cell therapy developer TiGenix NV licensed Swedish Orphan Biovitrum AB (Sobi) exclusive rights to commercialize its ChondroCelect for repairing cartilage defects of the ... [Published BioPortfolio - Apr 04 2014]
First reported Apr 01 2014 - Updated Apr 01 2014 - 5 reports

ORFADIN (Nitisinone) Capsule [SWEDISH ORPHAN BIOVITRUM AB (PUBL)]

First reported Mar 31 2014 - Updated Apr 01 2014 - 3 reports

US FDA clears Biogen Idec and SOBI’s Alprolix for hemophilia B

Marking a second regulatory hurdle for the breakthrough product, the US Food and Drug Administration late Friday approved biotech firm Biogen Idec’s (Nasdaq: BIIB) Alprolix, coagulation Factor IX (Recombinant), Fc Fusion Protein, for use in adults and ... [Published Pharma Letter - Mar 31 2014]
First reported Mar 27 2014 - Updated Mar 28 2014 - 2 reports

Swedish Orphan Biovitrum’s Pivotal Phase 3 Study Did Not Meet Primary Endpoint

Swedish Orphan Biovitrum AB (publ) (Sobi) today announced topline data from the company’s pivotal phase 3 study of its enzyme therapy Kiobrina (rhBSSL – recombinant human Bile Salt Stimulated Lipase). The primary endpoint of the study – growth velocity ... [Published BioPortfolio - Mar 28 2014]
First reported Mar 26 2014 - Updated Mar 26 2014 - 4 reports

Swedish Orphan Biovitrum Release: Kiobrina Pivotal Phase 3 Study Did Not Meet Primary Endpoint

(GLOBE NEWSWIRE) -- Swedish Orphan Biovitrum AB (publ) (Sobi) today announced topline data from the company's pivotal phase 3 study of its enzyme therapy Kiobrina (rhBSSL - recombinant human Bile Salt Stimulated Lipase). The primary endpoint of the study ... [Published BioSpace - Mar 26 2014]
First reported Mar 25 2014 - Updated Mar 26 2014 - 4 reports

EU approval for Cometriq in medullary thyroid carcinoma25-03-2014

The European Commission has approved Cometriq (cabozantinib), a drug for the treatment of adult patients with progressive, unresectable locally advanced or metastatic medullary thyroid carcinoma (MTC), from Swedish Orphan Biovitrum (STO: SOBI) and partner ... [Published Pharma Letter - Mar 26 2014]

Quotes

"We think we have priced (Alprolix) to create parity with existing therapies on an annual cost of therapy basis" Tony Kingsley, Biogen's head of global commercial operations, told Reuters in a telephone interview
"We anticipate that we will get reimbursement and coverage from payers for Alprolix" he said. "We don't foresee any unusual barriers on that front."
Boston, MA -- (SBWIRE) -- 04/16/2014 -- Global Markets Direct's, "Rheumatoid ', provides an overview of the Rheumatoid Arthritis's therapeutic pipeline."
...with hemophilia A and their parents," said Glenn Pierce, M D , Ph D , senior vice president of Hematology, Cell and Gene Therapies at Biogen Idec. "The results of this study support the potential for ELOCTATE to address a significant need for children with hemophilia A by providing prolonged intervals between scheduled prophylactic infusions to protect against bleeding episodes."

More Content

All (148) | News (99) | Reports (0) | Blogs (7) | Audio/Video (0) | Fact Sheets (2) | Press Releases (40)
sort by: Date | Relevance
UPDATE 1-EXCLUSIVE-Biogen prices hemophilia dru... [Published CNBC - 22 hours ago]
EXCLUSIVE : Biogen prices hemophilia drug on pa... [Published 4 Traders - Apr 18 2014]
Swedish Orphan Biovitrum Publishes Annual Repor... [Published BioSpace - Apr 16 2014]
Rheumatoid Arthritis - Pipeline Review, H1 2014... [Published Digital Journal - Apr 16 2014]
Sobi publishes Annual Report 2013 [Published NASDAQ OMX - Apr 16 2014]
Sobi publishes Annual Report 2013 [Published GlobeNewswire: Acquisitions News - Apr 16 2014]
Swedish Orphan Biovitrum : Sobi publishes Annua... [Published 4 Traders - Apr 16 2014]
Auxilium, Sobi present data from clinical trial... [Published PharmaBiz - Apr 15 2014]
Biogen and Sobi announce positive results from ... [Published Individual.com - Apr 14 2014]
Auxilium and Sobi Announce Encore Presentation ... [Published PR Newswire: General Business - Apr 14 2014]
JPMorgan Chase & Co. : JPMorgan Chase First Qua... [Published 4 Traders - Apr 14 2014]
Positive Data on Biogen/Sobi's Eloctate - Analy... [Published Nasdaq - Apr 11 2014]
Positive Data on Biogen/Sobi's Eloctate - Anal... [Published Benzinga.com - Apr 11 2014]
Positive Data on Biogen/Sobi's Eloctate - Anal... [Published Zacks.com - Apr 11 2014]
East Coast Biotech Roundup: Agios, Spero, Cerul... [Published Xconomy - Apr 11 2014]
Positive Data on Biogen/Sobi's Eloctate [Published Zacks.com - Apr 11 2014]
Hemophilia drug draws plaudits [Published Yahoo! Finance - Apr 11 2014]
Eloctate Performs Well in Phase III Trial of Pe... [Published FDA News - Apr 11 2014]
Positive Efficacy and Safety Results Reported F... [Published P&T Community - Apr 10 2014]
Healthcare Review: CVS Caremark, Rite Aid, Cell... [Published BioMedReports - Apr 10 2014]
Positive Ph III pediatric data for investigatio... [Published Pharma Letter - Apr 10 2014]
Hemophilia Drug Maintains Low Bleeding Rates in... [Published Drug Discovery and Development - Apr 10 2014]
Biogen's hemophilia hopeful scores a PhIII win ... [Published FierceBiotech - Apr 10 2014]
UPDATE 1-Biogen's blood disorder drug succeeds ... [Published CNBC - Apr 10 2014]
Biogen Idec, Sobi's Eloctate meets main goal of... [Published FirstWord Pharma - Apr 10 2014]
Biogen, Sobi haemophilia treatment maintains lo... [Published Seeking Alpha - Apr 10 2014]
Biogen Idec Reports Positive Top-line Results O... [Published RTTNews.com - Apr 10 2014]
Biogen Idec : , Sobi Say Hemophilia A Treatment... [Published 4 Traders - Apr 10 2014]
Biogen's blood disorder drug succeeds in late-s... [Published Yahoo! Health News - Apr 10 2014]
Biogen's blood disorder drug succeeds in late-s... [Published Yahoo! Finance - Apr 10 2014]
1 2 3 4 5
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Auxilium and Sobi Announce Encore Presentation ... [Published PR Newswire: General Business - Apr 14 2014]
CHESTERBROOK, Pa. and STOCKHOLM, April 14, 2014 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL) and Swedish Orphan Biovitrum AB (publ) (Sobi) today announced that encore data were presented from multiple clinical trials evaluating the use ...
Biogen's blood disorder drug succeeds in late-s... [Published Yahoo! Health News - Apr 10 2014]
(Reuters) - Biogen Idec Inc and Swedish Orphan Biovitrum said their experimental blood disorder drug was effective in maintaining low bleeding rates in children in a late-stage trial. The drug, Eloctate, was being developed as a treatment for haem... ...
Biogen Idec and Sobi Announce Positive Top-Line... [Published Business Wire Photo/Multimedia News - Apr 10 2014]
CAMBRIDGE, Mass. & STOCKHOLM--(BUSINESS WIRE)--Biogen Idec (NASDAQ: BIIB) and Swedish Orphan Biovitrum AB (publ) (Sobi) (STO: SOBI) today released positive top-line results of the Kids A-LONG Phase 3 clinical study that evaluated the safety and efficacy ...
Biogen Idec and Sobi Announce Positive Top-Line... [Published Business Wire Health News - Apr 10 2014]
CAMBRIDGE, Mass. & STOCKHOLM--(BUSINESS WIRE)--Biogen Idec (NASDAQ: BIIB) and Swedish Orphan Biovitrum AB (publ) (Sobi) (STO: SOBI) today released positive top-line results of the Kids A-LONG Phase 3 clinical study that evaluated the safety and efficacy ...
Biogen Idec and Sobi Announce Positive Top-Line... [Published Business Wire News with Multimedia - Apr 10 2014]
CAMBRIDGE, Mass. & STOCKHOLM--(BUSINESS WIRE)--Biogen Idec (NASDAQ: BIIB) and Swedish Orphan Biovitrum AB (publ) (Sobi) (STO: SOBI) today released positive top-line results of the Kids A-LONG Phase 3 clinical study that evaluated the safety and efficacy ...
1 2

Press Releases

sort by: Date | Relevance
Sobi publishes Annual Report 2013 [Published GlobeNewswire: Acquisitions News - Apr 16 2014]
Biogen Idec and Sobi announce positive top-line... [Published GlobeNewswire: Acquisitions News - Apr 10 2014]
Sobi becomes market authorisation holder for Xi... [Published GlobeNewswire: Advertising News - Apr 07 2014]
Notice of annual general meeting in Swedish Orp... [Published GlobeNewswire: Hardware News - Apr 03 2014]
Notice of annual general meeting in Swedish Orp... [Published GlobeNewswire: Acquisitions News - Apr 03 2014]
1 2 3 4 5 6 7 8
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.